Investigation of Novel and Established Therapies in a Human Intravenous Lipopolysaccharide Model of Sepsis

Sepsis is a common and life-threatening condition caused by a dysregulated host immune response to infection. Given the prominent role of endothelial breakdown and dysfunction in sepsis, therefore, there is an urgent need to establish strategies to protect the endothelium and preserve microcirculatory function. This study is a randomised clinical study investigating intravenous fluid therapy and oral imatinib therapy in healthy human volunteers exposed to intravenous lipopolysaccharide (LPS). The objective of the study is to investigate the biological effects of fluid and imatinib therapy on LPS-induced microcirculatory dysfunction.

NCT Number	NCT06626984
Lead Sponsor	Belfast Health and Social Care Trust Collaborators: Medical Research Council, The Royal College of Anaesthetists
Conditions	Sepsis, Fluid Overload, Endothelial Dysfunction, Microcirculation
Enrollment	65 participants
Start Date	2024-12-01
Primary Completion	2026-02-01 (estimated)
Study Completion	2026-07-01 (estimated)
Updated on ClinicalTrials.gov	2024-10-04